ISOSORBIDE DINITRATE

Post-LOE

isosorbide dinitrate

Hikma

ANDASUBLINGUALTABLET

Approved

Nov 1987

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

ISOSORBIDE DINITRATE (isosorbide dinitrate) by Hikma is clinical pharmacology the principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Approved for nitrate vasodilator [epc]. First approved in 1987.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY The principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to…

Worked on ISOSORBIDE DINITRATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ISOSORBIDE DINITRATE

Mechanism of Action

Indications